Disrupting the TRIB3-SQSTM1 interaction reduces liver fibrosis by restoring autophagy and suppressing exosome-mediated HSC activation

Abstract

Impaired macroautophagy/autophagy is involved in the pathogenesis of hepatic fibrosis. However, how aberrant autophagy promotes fibrosis is far from understood. Here, we aimed to define a previously unrevealed pro-fibrotic mechanism for the stress protein TRIB3 (tribbles pseudokinase 3)-mediated autophagy dysfunction. Human fibrotic liver tissues were obtained from patients with cirrhosis who underwent an open surgical repair process. The functional implications of TRIB3 were evaluated in mouse models of hepatic fibrosis induced by bile duct ligation (BDL) or thioacetamide (TAA) injection. Human fibrotic liver tissues expressed higher levels of TRIB3 and selective autophagic receptor SQSTM1/ p62 (sequestosome 1) than nonfibrotic tissues and the elevated expression of TRIB3 and SQSTM1 was positively correlated in the fibrotic tissues. Silencing Trib3 protected against experimentally induced hepatic fibrosis, accompanied by restored autophagy activity in fibrotic liver tissues. Furthermore, TRIB3 interacted with SQSTM1 and hindered its binding to MAP1LC3/LC3, which caused the accumulation of SQSTM1 aggregates and obstructed autophagic flux. The TRIB3-mediated autophagy impairment not only suppressed autophagic degradation of late endosomes but also promoted hepatocellular secretion of INHBA/Activin A-enriched exosomes which caused migration, proliferation and activation of hepatic stellate cells (HSCs), the effector cells of liver fibrosis. Disrupting the TRIB3-SQSTM1 interaction with a specific helical peptide exerted potent protective effects against hepatic fibrosis by restoring autophagic flux in hepatocytes and HSCs. Together, stress-elevated TRIB3 expression promotes hepatic fibrosis by interacting with SQSTM1 and interfering with its functions in liver-parenchymal cells and activating HSCs. Targeting this interaction is a promising strategy for treating fibroproliferative liver diseases.

Pancreatic β cell microRNA-26a alleviates type 2 diabetes by improving peripheral insulin sensitivity and preserving β cell function

“…In this study, we identified Inhba and Dnmt3a as direct targets of miR-26a in the liver. Inhba can act as a promoter of various chronic liver diseases such as liver fibrosis and cirrhosis [61,62]. Dnmt3a has recently been shown to be an epigenetic regulator of insulin resistance [63].…”

Antiproliferative effects of L‑asparaginase in acute myeloid leukemia

“…It is generally recognized that autophagy can have favorable and unfavorable outcomes in tumorigenesis and metastasis (40). Previous studies demonstrated that basal autophagy activation can modulate downstream signaling pathways that are involved in maintaining adequate HSC proliferation and differentiation (41). Impaired autophagy can result in the transformation of HSCs into a preleukemic state, increasing the likelihood of malignant leukemic transformation (42).…”

Shikonin reduces hepatic fibrosis by inducing apoptosis and inhibiting autophagy via the platelet‑activating factor‑mitogen‑activated protein kinase axis

“…Autophagy is an important strategy to maintain cell homeostasis (21). Autophagy is active in liver cells and maintains the normal physiological function of liver cells by eliminating easily accumulated proteins and damaged mitochondria (21)(22)(23). Additionally, autophagy is an important regulator implicated in various liver diseases (22).…”